title: [Histological study on healing of cryocautery-induced rat gastric ulcer treated with T-593].
abstract: The effect of T-593, a novel anti-ulcer agent, on the healing of cryocautery-induced rat gastric ulcer was investigated histologically in comparison with that of famotidine. Seven days after ulceration, T-593 (30 mg/kg) or famotidine (30 mg/kg) was orally administered twice daily for 8 weeks. Two, 4 and 8 weeks after the start of administration, the ulcer size was measured by a stereoscopic microscope, and the gastric mucosa was observed histologically. The thickness of the regenerated mucosa, the density and the arrangement of gastric glands, the degree of inflammatory-cell infiltration in the submucosal tissue and the number of microvessels in the submucosal tissue were quantified. In macroscopical evaluation, T-593 and famotidine significantly accelerated ulcer healing, and the time courses of the ulcer index were similar in both cases. In histological evaluation of healed ulcers, T-593 normalized the thickness of regenerated mucosa and reduced the degree of inflammatory-cell infiltration and the number of microvessels in the submucosal tissue, while famotidine had no effect. In conclusion, T-593 possesses accelerating effects not only on the restoration of regenerated mucosa but also on the maturation of submucosal tissue. Therefore, T-593 improves the quality of ulcer healing.
authors.affiliation: Research Laboratories, Toyama Chemical Co., Ltd., Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Doi
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: N
authors.initials: N
authors.lastname: Urata
authors.forename: M
authors.initials: M
authors.lastname: Mizuo
authors.forename: M
authors.initials: M
authors.lastname: Syoji
authors.forename: S
authors.initials: S
authors.lastname: Marubuchi
authors.forename: H
authors.initials: H
authors.lastname: Arai
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002425:Cautery; D015738:Famotidine / Q000008:administration & dosage / Q000627:therapeutic use; D005753:Gastric Mucosa / Q000473:pathology / Q000502:physiology; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration / Q000187:drug effects; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use*; D014945:Wound Healing
chemical_list: D000897:Anti-Ulcer Agents; D006146:Guanidines; D006635:Histamine H2 Antagonists; D013450:Sulfones; C088837:T 593; D015738:Famotidine